RE:Gilead's ADC Trodelvy comes up short in ER+/Her2- BCPatients who received Trodelvy went a median 5.5 months without tumor progression, a mere 1.5-month improvement over the median four months registered in the chemotherapy arm of the trial. And that small difference throws some doubt on the drugs value in this key potential market expansion opportunity. Advantage ONCY's pelareorep.